H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Arvinas Holding Company today and set a price target of $18.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Andrew Fein’s rating is based on Arvinas Holding Company’s promising pipeline developments, particularly with their ARV-102 and ARV-806 programs. The ARV-102 LRRK2 degrader has shown significant progress in penetrating the central nervous system and modulating biomarkers in Parkinson’s patients, which could be further validated by upcoming trials and external studies from Biogen/Denali. This progress suggests a potential de-risking of the entire target class, enhancing the company’s value proposition.
Additionally, the ARV-806 KRAS G12D degrader has demonstrated substantial potency and efficacy in preclinical models, showing over 25-fold potency compared to existing inhibitors and achieving notable tumor regressions. Its ability to synergize with immune checkpoint blockades positions it as a transformative asset in oncology. These developments indicate a strategic shift from focusing on vepdegestrant commercialization to executing a robust pipeline, with ARV-102 poised as a critical near-term catalyst, thereby justifying the Buy rating.
In another report released on November 3, BTIG also maintained a Buy rating on the stock with a $14.00 price target.